Related Experiment Video
Updated: Oct 24, 2025
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Stereotactic Radiosurgery for Olfactory Groove Meningiomas: An International, Multicenter Study
Adomas Bunevicius1, Jungeun Ahn1, Sarah Fribance1
1Department of Neurosurgery, University of Virginia, Charlottesville, Virginia, USA.
Background:
Stereotactic radiosurgery (SRS) is increasingly considered for selected olfactory groove meningiomas (OGMs).
Objective:
To investigate the safety and efficacy of SRS for OGMs.
Methods:
From 20 institutions participating in the International Radiosurgery Research Foundation, we pooled patients who underwent SRS for histologically confirmed or radiologically suspected WHO grade I OGMs and were followed for 6 mo or more after the SRS.
Results:
In total, 278 (median age 57 yr) patients underwent SRS for histologically confirmed (29%) or radiologically suspected (71%) WHO grade I OGMs Median treatment volume was 4.60 cm3 (range: 0.12-27.3 cm3), median prescription dose was 12 Gy, and median dose to the olfactory nerve was 11.20 Gy. During median post-SRS imaging follow-up of 39 mo (range: 6-240 mo), 43% of patients had partial or marginal response, 54% of patients had stable disease, and 3% of patients experienced progression. During median post-SRS clinical follow-up of 51 mo (range: 6-240 mo), 36 (13%) patients experienced clinical and/or radiological adverse radiation events (AREs). Elevated risk of AREs was associated with larger OGM volume (P = .009) and pre-SRS peritumoral T2/fluid-attenuated inversion-recovery signal abnormalities (P < .001). After the SRS, olfaction remained stable, improved, or deteriorated in 90%, 8%, and 2% of patients, respectively. Complete post-SRS anosmia was predicted by partial/complete anosmia before the SRS (odds ratio [OR] = 83.125; 95% CI [24.589-281.01], P < .001) and prior resection of OGM (OR = 3.919; 95% CI [1.713-8.970], P = .001).
Conclusion:
SRS is associated with durable local control of the majority of OGM patients with acceptable safety profile. SRS allows preservation or improvement of olfactory function in the majority of OGM patients.
Insights
Stereotactic radiosurgery (SRS) offers durable local control for olfactory groove meningiomas (OGMs) with a good safety profile. The majority of patients maintain or improve olfactory function after SRS treatment.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Olfactory groove meningiomas (OGMs) are tumors affecting the base of the skull.
- Stereotactic radiosurgery (SRS) is emerging as a treatment option for select OGMs.
Purpose of the Study:
- To evaluate the safety and effectiveness of SRS for treating OGMs.
- To assess long-term outcomes, including tumor control and olfactory function.
Main Methods:
- A multi-institutional study involving 20 centers from the International Radiosurgery Research Foundation.
- Pooled data from 278 patients with WHO grade I OGMs treated with SRS.
- Follow-up included imaging and clinical assessments for at least 6 months post-treatment.
Main Results:
- SRS demonstrated durable local control in most patients (97% stable or responding).
- Adverse radiation events (AREs) occurred in 13% of patients, with higher risk associated with larger tumor volume and pre-existing T2 signal abnormalities.
- Olfactory function was preserved or improved in 98% of patients post-SRS.
Conclusions:
- Stereotactic radiosurgery provides durable local control for olfactory groove meningiomas with an acceptable safety profile.
- SRS can preserve or improve olfactory function in the majority of treated patients, making it a viable option for selected cases.
